Figure 1. A 74-y-old man at initial staging with PSMA PET that demonstrates low uptake in primary tumor (A, arrowhead) and left pelvic side wall node (A, arrow). Bone scan was read as positive by 2 of ...
Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...
Extremely low rates of testing of bone mineral density (BMD), as recommended by recent guidelines, were found in a nationwide study of older men receiving androgen deprivation therapy (ADT) for the ...
Adverse Effects of Robotic-Assisted Laparoscopic Versus Open Retropubic Radical Prostatectomy Among a Nationwide Random Sample of Medicare-Age Men There is currently no imaging biomarker for ...
In a recent study published in Scientific Reports, a group of researchers investigated the differences in prostate magnetic resonance imaging (MRI) findings and clinical characteristics between ...
Health-related quality of life after IMRT or IMRT+ HDR brachytherapy for intermediate or high-risk prostate cancer: Five-year results of a prospective trial. This is an ASCO Meeting Abstract from the ...
Rarely has a footnote garnered so much positive attention, but a reference in the newly updated prostate cancer guidelines from the National Comprehensive Cancer Network (NCCN) has prostate cancer ...
Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate cancer care. The first application is initial s ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results